Blauvelt A, Warren R, Reich K, al. et. Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2019Mar.11 [cited 2024Jul.22];3(2):175. Available from: https://jofskin.org/index.php/skin/article/view/532